Departments of Radiopharmaceutical Cancer Research
Medicinal Radiochemistry(1), Dr. Sven Stadlbauer
- Small molecule and peptide-based radiotracer
- Preclinical Characterization of Radioconjugates
- Therapeutic Alpha-Emitters
- Multi-targeted Radiotheranostics
- Biological evaluation and modulation of targeted, radiometal-based bioconjugates
Radiopharmaceutical and Chemical Biology(2), Prof. Dr. Jens Pietzsch
- Radiotracer and Drug Development
- Theranostic Targets and Experimental Models
- Radiopharmacology and Cancer Imaging
- Tissue Remodeling and Inflammation Imaging
- Radiometals and Functional Labeling Chemistry
- Metabolic and Immune Imaging Biomarkers
Positron Emission Tomography(3), Prof. Dr. Jörg van den Hoff
- Improved quantification of functional information in oncological PET
- Quantitative perfusion imaging using functional ASL-MRI
- Multimodal imaging and assessment of in vivo quantification accuracy
- Motion compensation methods for PET
- High resolution PET image reconstruction
Radioimmunology(4), Dr. Anja Feldmann
- Antibody-based immunotheranostics for tumor therapy and diagnosis
- Adapter CAR-based immunotheranostics for personalized immunotherapy and diagnosis
- Modulation of tumor microenvironment
- Development of immuno- and radiotherapy
- Personalized immunotheranostics for acute myeloid leukemia
Nano-Microsystems for Life Sciences(5), Dr. Larysa Baraban
- Bionanoelectronics
- 3D Bioreactors
- Droplets microfluidics for clinical diagnostics
Neuroradiopharmaceuticals(6), Prof. Dr. Klaus Kopka/Prof. Dr. Michael Bachmann (provisional)
- Molecular imaging of adenosine signalling in cancer
- Molecular imaging of α7 nAChR in cancer and brain diseases
- [18F]Flubatine - a potential PET marker of early Alzheimer`s disease
- Development of new ligands and 18F-radiotracers for the vesicular acetylcholine transporter (VAChT) in brain
- New PET Radioligands for Imaging of Cannabinoid Receptors Type 2 (CB2) in the Human Brain
- Radioligands for PET Imaging of Cyclic Nucleotide Phosphodiesterases 2A, 5A and 10A
- Development of 18F-labelled PET radiotracers for the imaging of σ receptors in cancer and brain diseases
Targetry, Target Chemistry and Radiopharmacy(7), Dr. Martin Kreller
- Production of radioisotopes at the proton accelerator cyclotron TR-Flex by means of (p,X) nuclear reactions.
- Development of new target technology, target preparation processes and processes for the separation and preparation of radionuclides.
- Supply of the Institute for Radiopharmaceutical Cancer Research and external cooperation partners with radionuclides for research and development such as 18F, 11C, 64Cu, 67Cu, 131Ba, 133La, 197(m)Hg, ...
- Providing PET radiopharmaceuticals for daily clinical use (18F-FDG, 18F-FDOPA, 18F-PSMA-1007, 18F-FMISO, 11C-methionine) according to GMP and AMG including quality control.
- GMP-compliant transfer of newly developed radiotracers and manufacturing processes into clinical application.
- Scaling of the processes for the generation of radionuclides and the production of radiopharmaceuticals to industrial scale and knowledge transfer to industrial partners.
- Cooperation with external accelerator facilities to integrate alternative nuclear reactions into the nuclide production process.
URL of this article
https://www.hzdr.de/db/Cms?pOid=10220
Contact
Prof. Dr. Klaus Kopka
Director Institute of Radiopharmaceutical Cancer Research
k.kopkahzdr.de
Phone: +49 351 260 2060
Prof. Dr. Michael Bachmann
Director Institute of Radiopharmaceutical Cancer Research
m.bachmannhzdr.de
Phone: +49 351 260 3170
+49 351 458 2101
Marita Kersten
Secretariat / Administration
Institute of Radiopharmaceutical Cancer Research
m.kerstenhzdr.de
Phone: +49 351 260 3223
More information